SCHEMBL379554

SCHEMBL379554

Cc1ccc(-c2csc3c(-c4cccnc4)cnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.52
CYP3A4 P08684 5/20 0.51
CYP1A2 P05177 4/20 0.51
CYP2D6 P10635 3/20 0.51
CYP2C19 P33261 3/20 0.51
HSD17B10 Q99714 2/20 0.51
ALOX15 P16050 1/20 0.51
KDR P35968 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PDE5A O76074 2/20 0.47
MAPT P10636 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
ALDH1A1 P00352 3/20 0.45
USP1 O94782 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379662 0.93 CCNC (0.49) BRAFCYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL379876 0.92 BTK (0.47) BRAFCYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL379874 0.92 CCNC (0.47) BRAFCYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL379469 0.89 ESR1 (0.49) BRAFKDRCCNCCDK8AURKB
SCHEMBL379543 0.87 THRB (0.44) CYP3A4CYP1A2CYP2D6CYP2C19HSD17B10
SCHEMBL380180 0.86 ESR1 (0.50) BRAFCYP3A4KDRCCNCCDK8
SCHEMBL379842 0.85 CYP1A2 (0.54) CYP3A4CYP1A2CYP2D6CYP2C19HSD17B10
SCHEMBL379872 0.85 CCNC (0.42) BRAFCYP3A4CYP1A2CYP2D6CYP2C19
SCHEMBL379947 0.84 KDR (0.45) BRAFCYP3A4KDRCCNCCDK8
SCHEMBL379184 0.84 KDR (0.49) BRAFCYP3A4KDRCCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US claimed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 BRAF 139/4885CYP3A4 690/4885CYP1A2 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.